DUBLIN – Galecto Biotech AB raised €79 million (US$89.9 million) in a series C round to take its lead galectin-3 inhibitor, TD-139, into a phase II/III trial in idiopathic pulmonary fibrosis (IPF) and to move two additional compounds employing the same mechanism into trials in other fibrotic indications and, potentially, cancer.